’ve been writing too many positive stories lately. They’re ruining my reputation as the Night King of Biotech. This column is a return to normalcy.
First up: It pays to read 10-Qs. Sometimes, you find biotech companies trying to slip alarming nuggets into their quarterly filings with the Securities and Exchange Commission. Take, for example, Geron (GERN), which used its most recent 10-Q to warn investors about an inquiry from the Food and Drug Administration that puts the continued clinical development of its only drug, imetelstat, at risk.